[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100422948":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":22,"interventions":34,"overallOfficials":44,"centralContacts":48,"locations":54,"responsibleParty":75,"collaborators":77,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":13,"eligibilityCriteria":87,"healthyVolunteers":83,"sex":88,"minAge":89,"maxAge":13,"enrollmentInfo":90,"targetDuration":13,"studyType":93,"phases":94,"briefSummary":97,"conditions":98,"keywords":13,"overallStatus":56,"whyStopped":13,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Price Vision Group","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"corneal neovascularization as a proportion of the total corneal area","the cornea will be photographed and morphometric image analysis software will be used to measure corneal neovascularization as a proportion of the total corneal area. The proportion measured at baseline will be compared with the proportion measured at 6 months after treatment.","6 months",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":20},"SINGLE",[21],"OUTCOMES_ASSESSOR",[23,29],{"label":24,"type":25,"description":26,"interventionNames":27},"30 minute photoactivation","ACTIVE_COMPARATOR","photoactivation of riboflavin 0.1% using 365-nm UV light, 3mW\u002Fcm2 for 30 minutes",[28],"Combination Product: 30 minute photoactivation of riboflavin 0.1%",{"label":30,"type":25,"description":31,"interventionNames":32},"10 minute photoactivation","photoactivation of riboflavin 0.1% using 365-nm UV light, 9mW\u002Fcm2 for 10 minutes",[33],"Combination Product: 10 minute photoactivation of riboflavin 0.1%",[35,40],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":13},"COMBINATION_PRODUCT","30 minute photoactivation of riboflavin 0.1%","Use of riboflavin 0.1% eye drops and 3mW\u002Fcm2 UVA light for 30 minutes",[24],{"type":36,"name":41,"description":42,"armGroupLabels":43,"otherNames":13},"10 minute photoactivation of riboflavin 0.1%","Use of riboflavin 0.1% eye drops and 9mW\u002Fcm2 UVA light for 10 minutes",[30],[45],{"name":46,"affiliation":5,"role":47},"Francis W Price, Jr., MD","PRINCIPAL_INVESTIGATOR",[49],{"name":50,"role":51,"phone":52,"phoneExt":13,"email":53},"Marianne Price, PhD","CONTACT","317-814-2990","mprice@cornea.org",[55],{"facility":5,"status":56,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"RECRUITING","Indianapolis","Indiana","46260","United States","US",{"type":63,"coordinates":64},"Point",[65,66],-86.15804,39.76838,{"lat":66,"lon":65},[69,70,72],{"name":50,"role":51,"phone":52,"phoneExt":13,"email":53},{"name":71,"role":47,"phone":13,"phoneExt":13,"email":13},"Francis Price, Jr., MD",{"name":73,"role":74,"phone":13,"phoneExt":13,"email":13},"Matthew Feng, MD","SUB_INVESTIGATOR",{"type":76,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR",[78],{"name":79,"class":80},"Cornea Research Foundation of America","OTHER","100422948","phase-2-corneal-crosslinking-for-treatment-of-corneal-neovascularization-100422948",false,"NCT04787471","Corneal Crosslinking for Treatment of Corneal Neovascularization","Randomized Comparison of Standard vs. Accelerated Corneal Crosslinking for Treatment of Corneal Neovascularization With or Without Concomitant Inflammation and\u002For Infection","Inclusion Criteria:\n\n* 18 years of age or older\n* With active inflammation or infection causing vascularization and possibly melting of the cornea, or vessels extending into the cornea causing lipid deposition, or vascularization that could significantly increase the risk of rejection of a current or planned corneal transplant, or vessels that continue to extend into the cornea despite topical treatment with corticosteroids.\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Known sensitivity to treatment medications\n* Current condition that in the investigator's opinion could compromise safety or data integrity.\n* Pregnancy (including plan to become pregnant) or lactation during the course of the study","ALL","18 Years",{"count":91,"type":92},138,"ESTIMATED","INTERVENTIONAL",[95,96],"PHASE2","PHASE3","The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and\u002For infection.",[99],"Corneal Neovascularization","2026-09-14",{"date":102,"type":103},"2026-09-17","ACTUAL",{"date":105,"type":103},"2021-05-03",{"date":107,"type":92},"2029-09-15",{"name":5,"class":6},1]